| Telemetry | Personal contact | p-value (telemetry vs. personal contact) | p-value (telemetry vs. remote + phone vs. visit) | ||
---|---|---|---|---|---|---|
 | (N = 102) n (%) / mean ± SD | All (N = 108) n (%) / mean ± SD | Remote + phone (N = 53) n (%) / mean ± SD | Visit (N = 55) n (%) / mean ± SD | ||
Age (years) | 62.5 ± 12.2 | 65.1 ± 10.1 | 64.7 ± 9.1 | 65.4 ± 11.1 | 0.192 | 0.312 |
Female (%) | 17 (16.7) | 16 (14.8) | 7 (13.2) | 9 (16.4) | 0.712 | 0.844 |
Disease parameters | ||||||
 LVEF (%) | 28.2 ± 7.1 | 28.3 ± 8.9 | 29.7 ± 10.8 | 26.9 ± 6.5 | 0.368 | 0.562 |
 NYHA class (mean ± SD) | 2.4 ± 0.6 | 2.3 ± 0.7 | 2.3 ± 0.7 | 2.3 ± 0.7 | 0.524 | 0.804 |
 NYHA class (median) | 2 (range 1–3) | 2 (range 1–3) | 2 (range 1–3) | 2 (range 1–3) |  |  |
  NYHA I | 7.8 | 12.0 | 13.2 | 10.9 |  |  |
  NYHA II | 48.0 | 46.3 | 43.4 | 49.1 |  |  |
  NYHA III | 44.1 | 41.7 | 43.4 | 40.0 |  |  |
 Cardiac disease type |  |  |  |  | 0.834 | 0.357 |
  None (%) | 0 (0.0) | 1 (0.9) | 1 (1.9) | 0 (0.0) |  |  |
  Ischemic (%) | 58 (56.9) | 66 (61.1) | 30 (56.6) | 36 (65.5) |  |  |
  Non-ischemic (%) | 41 (40.2) | 38 (35.2) | 19 (35.8) | 19 (34.5) |  |  |
  Other (%) | 3 (2.9) | 3 (2.8) | 3 (5.7) | 0 (0.0) |  |  |
 ICD indication |  |  |  |  | 0.861 | 0.508 |
  Primary prevention | 86 (84.3) | 92 (85.2) | 43 (81.1) | 49 (89.1) |  |  |
  Secondary prevention | 16 (15.7) | 16 (14.8) | 10 (18.9) | 6 (10.9) |  |  |
Cardiac medication | ||||||
 None | 5 (4.9) | 9 (8.3) | 4 (7.5) | 5 (9.1) | 0.319 | 0.578 |
 Class 2 (beta-blockers) | 96 (94.1) | 99 (91.7) | 49 (92.5) | 50 (90.9) | 0.491 | 0.751 |
 Class 4 | 1 (1.0) | 1 (0.9) | 1 (1.9) | 0 (0.0) | 1.0 | 0.744 |
 Amiodarone | 12 (11.8) | 12 (11.1) | 5 (9.5) | 7 (12.7) | 0.882 | 0.856 |
Cardiac medication | ||||||
 Diuretics | 87 (85.3) | 89 (82.4) | 43 (81.1) | 46 (83.6) | 0.570 | 0.800 |
 ACE inhibitors | 81 (79.4) | 86 (79.6) | 38 (71.7) | 48 (87.3) | 0.969 | 0.134 |
 ARB | 18 (17.6) | 16 (14.8) | 10 (18.9) | 6 (10.9) | 0.578 | 0.456 |
 Spironolactone | 54 (53.5) a | 61 (56.5) | 28 (52.8) | 33 (60.0) | 0.661 | 0.686 |
Device type | Â | Â | Â | Â | 0.320 | 0.313 |
 ICD Single Chamber | 57 (55.9) | 51 (47.2) | 27 (50.9) | 24 (43.6) |  |  |
 ICD Dual Chamber | 13 (12.7) | 21 (19.4) | 12 (22.6) | 9 (16.4) |  |  |
 CRT-D | 32 (31.4) | 36 (33.3) | 14 (26.4) | 22 (40.0) |  |  |
DF-4 connector | 73 (71.6) | 77 (71.3) | 36 (67.9) | 41 (74.5) | 0.965 | 0.748 |
MLHFQ score PHD | 33.6 ± 22.0 | 33.3 ± 22.0 | 33.7 ± 24.7 | 33.0 ± 19.3 | 0.861 | 0.976 |
MLHFQ score at 1 M | 24.0 ± 20.3 | 21.8 ± 19.3 | 22.8 ± 23.7 | 20.9 ± 14.2 | 0.543 | 0.631 |